Trial Outcomes & Findings for Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers (NCT NCT02230579)
NCT ID: NCT02230579
Last Updated: 2019-07-17
Results Overview
Subject will be in-house up to D3, and then have a follow up visit at the site on D5, 7, 10, 14, 19, 26, 29 or longer according to half life
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
48 participants
Primary outcome timeframe
up to D29 or longer according to half life
Results posted on
2019-07-17
Participant Flow
For the purposes of this study, subjects that were re-used in SAD6 were treated as separate subjects, i.e. the entire trial population comprised 48 subjects, eight subjects in 6 cohorts.
Participant milestones
| Measure |
Cohort SAD1 Fasted
5mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Placebo: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD2 Fasted
20mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Placebo: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD3 Fasted
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Placebo: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD4 Fasted
80mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Placebo: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD5 Fasted
120mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Placebo: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD6 Fed
Reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability.
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Placebo: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Placebo
Placebo to match MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose Two volunteers within each cohort (SAD1 to SAD6) were scheduled to receive placebo in a double blind manner.
|
|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
6
|
6
|
6
|
6
|
6
|
6
|
12
|
|
Overall Study
COMPLETED
|
6
|
6
|
6
|
6
|
6
|
6
|
12
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers
Baseline characteristics by cohort
| Measure |
Cohort SAD1 Fasted
n=6 Participants
5mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD2 Fasted
n=6 Participants
20mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD3 Fasted
n=6 Participants
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD4 Fasted
n=6 Participants
80mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD5 Fasted
n=6 Participants
120mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD6 Fed
n=6 Participants
Cohort SAD6, reusing volunteers from previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Placebo
n=12 Participants
Placebo to match MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Two volunteers within each cohort (SAD1 to SAD6) were scheduled to receive placebo in a double blind manner.
|
Total
n=48 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
29.3 years
n=5 Participants
|
34 years
n=7 Participants
|
37 years
n=5 Participants
|
30 years
n=4 Participants
|
23.7 years
n=21 Participants
|
34 years
n=8 Participants
|
32.7 years
n=8 Participants
|
31.7 years
n=24 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
8 Participants
n=24 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
4 Participants
n=8 Participants
|
11 Participants
n=8 Participants
|
40 Participants
n=24 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Black or African American
|
4 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
4 Participants
n=8 Participants
|
9 Participants
n=8 Participants
|
35 Participants
n=24 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
12 Participants
n=24 Participants
|
PRIMARY outcome
Timeframe: up to D29 or longer according to half lifeSubject will be in-house up to D3, and then have a follow up visit at the site on D5, 7, 10, 14, 19, 26, 29 or longer according to half life
Outcome measures
| Measure |
Cohort SAD1 Fasted
n=6 Participants
5mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD2 Fasted
n=6 Participants
20mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD3 Fasted
n=6 Participants
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD4 Fasted
n=6 Participants
80mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD5 Fasted
n=6 Participants
120mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD6 Fed
n=6 Participants
Cohort SAD6, reusing volunteers from previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Placebo
n=12 Participants
Placebo to match MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Two volunteers within each cohort (SAD1 to SAD6) were scheduled to receive placebo in a double blind manner.
|
|---|---|---|---|---|---|---|---|
|
Number of Participants With Adverse Events
|
4 Participants
|
5 Participants
|
5 Participants
|
6 Participants
|
6 Participants
|
6 Participants
|
11 Participants
|
PRIMARY outcome
Timeframe: 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 216, 312, 432, 600, 672 hours post-dosePopulation: One subject (SAD5 120 mg) was excluded from the PK analysis population due to concomitant use of prohibited medications known to produce drug-drug interactions with pharmacokinetic consequences.
Pk blood collection - additional PK point may be planned final visit depending on emerging PK data, unnecessary PK points could be eliminated for the latter cohorts Investigate the effect of food on the pharmacokinetic and tolerability of the investigational drug in cohort 4 and 8
Outcome measures
| Measure |
Cohort SAD1 Fasted
n=6 Participants
5mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD2 Fasted
n=6 Participants
20mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD3 Fasted
n=6 Participants
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD4 Fasted
n=6 Participants
80mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD5 Fasted
n=5 Participants
120mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD6 Fed
n=6 Participants
Cohort SAD6, reusing volunteers from previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Placebo
Placebo to match MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Two volunteers within each cohort (SAD1 to SAD6) were scheduled to receive placebo in a double blind manner.
|
|---|---|---|---|---|---|---|---|
|
Area Under the Plasma Concentration Versus Time Curve (AUC) of MMV390048
|
2136.9 h*ng/mL
Interval 903.1 to 3718.7
|
32727.2 h*ng/mL
Interval 24895.2 to 38914.3
|
21050.7 h*ng/mL
Interval 6325.4 to 37934.6
|
58668.2 h*ng/mL
Interval 40246.0 to 125655.1
|
156036.2 h*ng/mL
Interval 13053.0 to 208989.4
|
29004.6 h*ng/mL
Interval 15775.1 to 72735.3
|
—
|
PRIMARY outcome
Timeframe: 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 216, 312, 432, 600, 672 hours post-dosePopulation: One subject (SAD5 120 mg) was excluded from the PK analysis population due to concomitant use of prohibited medications known to produce drug-drug interactions with pharmacokinetic consequences.
Pk blood collection Investigate the effect of food on the pharmacokinetic and tolerability of the investigational drug in cohort 4 and 8
Outcome measures
| Measure |
Cohort SAD1 Fasted
n=6 Participants
5mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD2 Fasted
n=6 Participants
20mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD3 Fasted
n=6 Participants
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD4 Fasted
n=6 Participants
80mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD5 Fasted
n=5 Participants
120mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD6 Fed
n=6 Participants
Cohort SAD6, reusing volunteers from previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Placebo
Placebo to match MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Two volunteers within each cohort (SAD1 to SAD6) were scheduled to receive placebo in a double blind manner.
|
|---|---|---|---|---|---|---|---|
|
Half-life of MMV390048
|
163.1 hours
Interval 86.9 to 297.0
|
326.1 hours
Interval 221.6 to 348.0
|
192.6 hours
Interval 84.2 to 486.2
|
200.3 hours
Interval 154.1 to 457.1
|
252.3 hours
Interval 132.5 to 263.5
|
210.8 hours
Interval 111.3 to 461.1
|
—
|
SECONDARY outcome
Timeframe: up to 144 hr post dosePopulation: Samples received from the remaining participants were not processed due to the fact that they were either placebo samples, or failed to reach the pre-determined in vitro IC50 of MMV390048.
Blood collection to determine efficacy of investigational drug against parasites using an ex vivo malaria assay - this was done only for cohort 3 The experimentally obtained bioassay IC50 values were determined and compared to IC50 obtained with reference serum sample spiked with a known amount of MMV390048 titrated into the P. falciparum assay.
Outcome measures
| Measure |
Cohort SAD1 Fasted
5mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD2 Fasted
20mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD3 Fasted
n=2 Participants
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD4 Fasted
80mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD5 Fasted
120mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD6 Fed
Cohort SAD6, reusing volunteers from previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Placebo
Placebo to match MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
Two volunteers within each cohort (SAD1 to SAD6) were scheduled to receive placebo in a double blind manner.
|
|---|---|---|---|---|---|---|---|
|
Determine ex Vivo Efficacy (IC50)
|
—
|
—
|
9.475 ng/ml
Interval 9.1 to 9.85
|
—
|
—
|
—
|
—
|
Adverse Events
Cohort SAD1 Fasted
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Cohort SAD2 Fasted
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
Cohort SAD3 Fasted
Serious events: 0 serious events
Other events: 5 other events
Deaths: 0 deaths
Cohort SAD4 Fasted
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Cohort SAD5 Fasted
Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths
Cohort SAD6 Fed
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Placebo
Serious events: 0 serious events
Other events: 11 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Cohort SAD1 Fasted
n=6 participants at risk
5mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD2 Fasted
n=6 participants at risk
20mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD3 Fasted
n=6 participants at risk
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD4 Fasted
n=6 participants at risk
80mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD5 Fasted
n=6 participants at risk
120mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD6 Fed
n=6 participants at risk
Cohort SAD6, reusing volunteers from previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability 40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Placebo
n=12 participants at risk
Placebo to match MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose Two volunteers within each cohort (SAD1 to SAD6) were scheduled to receive placebo in a double blind manner.
|
|---|---|---|---|---|---|---|---|
|
Nervous system disorders
generalised myoclonus
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/12
|
Other adverse events
| Measure |
Cohort SAD1 Fasted
n=6 participants at risk
5mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD2 Fasted
n=6 participants at risk
20mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD3 Fasted
n=6 participants at risk
40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD4 Fasted
n=6 participants at risk
80mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD5 Fasted
n=6 participants at risk
120mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Cohort SAD6 Fed
n=6 participants at risk
Cohort SAD6, reusing volunteers from previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability 40mg of MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose
|
Placebo
n=12 participants at risk
Placebo to match MMV390048: Single administration, supplied as "powder in bottle" formulation for reconstitution pre-dose Two volunteers within each cohort (SAD1 to SAD6) were scheduled to receive placebo in a double blind manner.
|
|---|---|---|---|---|---|---|---|
|
Investigations
Neutrophil count decreased
|
0.00%
0/6
|
0.00%
0/6
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/6
|
16.7%
1/6
|
0.00%
0/12
|
|
Nervous system disorders
Diziness
|
0.00%
0/6
|
0.00%
0/6
|
33.3%
2/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/12
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/6
|
16.7%
1/6
|
16.7%
1/6
|
16.7%
1/6
|
0.00%
0/6
|
33.3%
2/6
|
8.3%
1/12
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/6
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
16.7%
1/6
|
0.00%
0/12
|
|
Cardiac disorders
Palpitation
|
0.00%
0/6
|
0.00%
0/6
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
8.3%
1/12
|
|
Infections and infestations
Medical device site reaction
|
50.0%
3/6
|
0.00%
0/6
|
16.7%
1/6
|
83.3%
5/6
|
50.0%
3/6
|
83.3%
5/6
|
41.7%
5/12
|
|
General disorders
Influenza like illness
|
0.00%
0/6
|
33.3%
2/6
|
33.3%
2/6
|
33.3%
2/6
|
0.00%
0/6
|
16.7%
1/6
|
16.7%
2/12
|
|
General disorders
Headache
|
0.00%
0/6
|
16.7%
1/6
|
33.3%
2/6
|
16.7%
1/6
|
16.7%
1/6
|
16.7%
1/6
|
8.3%
1/12
|
|
Blood and lymphatic system disorders
Blood CK increased
|
0.00%
0/6
|
0.00%
0/6
|
50.0%
3/6
|
16.7%
1/6
|
33.3%
2/6
|
0.00%
0/6
|
0.00%
0/12
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/6
|
0.00%
0/6
|
16.7%
1/6
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/6
|
8.3%
1/12
|
|
General disorders
Contusion
|
50.0%
3/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/12
|
|
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract infection
|
0.00%
0/6
|
16.7%
1/6
|
16.7%
1/6
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/12
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
16.7%
1/6
|
8.3%
1/12
|
|
General disorders
Fatigue
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
16.7%
2/12
|
|
Skin and subcutaneous tissue disorders
Furuncle
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/6
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/12
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
16.7%
1/6
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/12
|
|
Skin and subcutaneous tissue disorders
Thermal burn
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
33.3%
2/6
|
0.00%
0/12
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/6
|
16.7%
1/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
0.00%
0/6
|
8.3%
1/12
|
Additional Information
Dr Cristina Donini - Associate Director
Medicines for Malaria Venture
Phone: 00 41 22 555 03 12
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place